Importance Macrolide antibiotics have been shown beneficial in cystic fibrosis (CF) and
diffuse panbronchiolitis, and earlier findings also suggest a benefit in non-CF …

Background Azithromycin is a macrolide antibiotic with anti-inflammatory and
immunomodulatory properties. We tested the hypothesis that azithromycin would decrease …

Background Bronchiectasis guidelines recommend long-term macrolide treatment for
patients with three or more exacerbations per year without Pseudomonas aeruginosa …

We describe our institutional efficacy experience of azithromycin 250mg thrice weekly in
adult non-cystic fibrosis bronchiectasis. METHODS: Eligibility criteria for prophylactic …

Importance Macrolide antibiotics such as erythromycin may improve clinical outcomes in
non–cystic fibrosis (CF) bronchiectasis, although associated risks of macrolide resistance …

Introduction Bronchiectasis is a chronic pulmonary process characterized by recurrent
respiratory infections leading to destruction of airways secondary to inflammation. We …

Long‐term macrolides are increasingly being prescribed for stable bronchiectasis. This meta‐
analysis assessed the clinical effect of this treatment in bronchiectasis. A systematic review …

Rationale: Chronic azithromycin is commonly used in cystic fibrosis based on short
controlled clinical trials showing reductions in pulmonary exacerbations and improved …

Bronchiectasis is a complex, chronic respiratory condition, characterized by frequent cough
and exertional dyspnea due to a range of conditions that include inherited mucociliary …

Background: Relentless chronic pulmonary inflammation is the major contributor to morbidity
and mortality in patients with cystic fibrosis (CF). While immunomodulating therapies such as …